Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]
Citius Oncology, Inc. (CTOR)
Company Research
Source: Yahoo! Finance
Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,142,858 shares of common stock in a registered direct offering. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 5,142,858 shares of common stock. The combined effective offering price for each share of common stock and accompanying warrant is . The warrants will have an exercise price of per share, will be exercisable six months from the date of issuance, and will expire on the five and one-half year anniversary from the date of issuance. Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.) The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approxim
Show less
Read more
Impact Snapshot
Event Time:
CTOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTOR alerts
High impacting Citius Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CTOR
News
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimPR Newswire
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) [Yahoo! Finance]Yahoo! Finance
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)PR Newswire
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingPR Newswire
CTOR
Sec Filings
- 12/1/25 - Form 8-K
- 12/1/25 - Form 4/A
- 12/1/25 - Form 4/A
- CTOR's page on the SEC website